Implementation of capecitabine (Xeloda®) into a cancer centre: UK experience
- 1 January 2004
- journal article
- review article
- Published by Elsevier BV in European Journal of Oncology Nursing
- Vol. 8, S54-S62
- https://doi.org/10.1016/j.ejon.2004.06.009
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- The vital role of education and information in patients receiving capecitabine (Xeloda®)European Journal of Oncology Nursing, 2004
- Patient Education: The Cornerstone of Successful Oral Chemotherapy TreatmentClinical Journal of Oncology Nursing, 2003
- A Changing Paradigm for Cancer Treatment: The Advent of New Oral Chemotherapy AgentsClinical Journal of Oncology Nursing, 2003
- 271 Savings in staff time as a result of switching from De Gramont to oral capecitabine for patients with advance colorectal cancerEuropean Journal of Cancer Supplements, 2003
- First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorinAnnals of Oncology, 2002
- Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III StudyJournal of Clinical Oncology, 2001
- Reviewing audit: barriers and facilitating factors for effective clinical auditQuality in health care : QHC, 2000
- Implementing findings of researchBMJ, 1994
- Infectious Complications of Indwelling Long-term Central Venous CathetersSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1990
- Clinical Pharmacology of 5-FluorouracilClinical Pharmacokinetics, 1989